| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.11.25 | Listing of subscription rights and paid subscription shares of Bioextrax AB | 312 | GlobeNewswire | With effect from November 27, 2025, the subscription rights in Bioextrax AB will be traded on First North Growth Market. Trading will continue up until and including December 08, 2025.
Instrument:
Subscription... ► Artikel lesen | |
| 24.11.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 24.11.2025 | 324 | Xetra Newsboard | Das Instrument WTGA IE000TB3YTV4 WSDMTR.GL AUTO.INNO.DLACC ETF wird cum Kapitalmassnahme gehandelt am 24.11.2025 und ex Kapitalmassnahme am 25.11.2025 The instrument WTGA IE000TB3YTV4 WSDMTR.GL AUTO.INNO.DLACC... ► Artikel lesen | |
| BIOEXTRAX Aktie jetzt für 0€ handeln | |||||
| 20.11.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 20.11.2025 | 434 | Xetra Newsboard | Das Instrument 6QZ AU0000107211 TOMBADOR IRON LTD. EQUITY wird cum Kapitalmassnahme gehandelt am 20.11.2025 und ex Kapitalmassnahme am 21.11.2025 The instrument 6QZ AU0000107211 TOMBADOR IRON LTD. EQUITY... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,576 | -2,94 % | KURSZIEL ANGEHOBEN bei Valneva: Steht hier der Beginn einer neuen Rally? - Verpassen Sie das nicht | ||
| AMGEN | 292,40 | -0,90 % | $1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today | ||
| EPIGENOMICS | 0,920 | +5,75 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| STRYKER | 288,00 | -0,45 % | Stryker To Buy Amplitude Vascular Systems | WASHINGTON (dpa-AFX) - Stryker Corporation (SYK), a medical technology company, said on Monday that it has signed a deal to buy Amplitude Vascular Systems, Inc., a privately held developer of... ► Artikel lesen | |
| OCUGEN | 1,708 | +3,64 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| BIO-GATE | 0,630 | +7,69 % | Bio-Gate: Operativer Wendepunkt | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die Bio-Gate AG im ersten Halbjahr des Geschäftsjahres 2025 (per 31.12.) einen Umsatz von 3,44 Mio. Euro (HJ 2024:... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,280 | -0,76 % | Johnson Fistel, PLLP: Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty | San Diego, California--(Newsfile Corp. - January 12, 2026) - Shareholder rights law firm Johnson Fistel, PLLP is investigating potential shareholder derivative claims on behalf of Sarepta Therapeutics... ► Artikel lesen | |
| 10X GENOMICS | 21,200 | -1,35 % | Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs | While foundation models for language have thrived on vast digital datasets, biology has long lacked the standardized, high-quality data scale required for a similar breakthrough, particularly for clinical... ► Artikel lesen | |
| USANA HEALTH SCIENCES | 15,700 | +1,95 % | USANA Health Sciences tritt AVEDISCO als Vollmitglied bei | ||
| BIO-TECHNE | 50,56 | +1,96 % | Bio-Techne's Ella Immunoassay Platform Receives CE-IVD Marking In EU | WASHINGTON (dpa-AFX) - Bio-Techne Corp. (TECH) said its Ella benchtop immunoassay platform has received CE-IVD marking and is now available for clinical use across the European Union. The CE-IVD... ► Artikel lesen | |
| VERACYTE | 29,510 | +2,36 % | Jefferies stuft Veracyte mit "Buy" ein - starkes Wachstum im Diagnostikgeschäft erwartet | ||
| INNATE PHARMA | 1,424 | 0,00 % | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026 | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| XENON PHARMACEUTICALS | 49,600 | -0,40 % | Xenon Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| PROTARA THERAPEUTICS | 4,352 | -1,36 % | Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update | Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients Company expects... ► Artikel lesen | |
| NUCANA | 2,220 | 0,00 % | NuCana plc: NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update | NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma
Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026
Advancing... ► Artikel lesen |